C:\Program Files\Stnexp\Queries\09840503.str

search of claim 2 R^2 is monocyclic





chain nodes :
11 14 16
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
3-16 7-11 9-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
3-16 5-7 6-10 7-8 7-11 8-9 9-10 9-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:CN,O,S,Hy

G2:C,Cy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
14:CLASS 16:CLASS
Generic attributes :
16:
Saturation : Unsaturated
Type of Ring System : Monocyclic

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 41	Jan 21	PHARMAML offering one free connect hour in February 2003

NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:59:59 ON 04 FEB 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 11:01:24 ON 04 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2003 HIGHEST RN 485316-86-7
DICTIONARY FILE UPDATES: 3 FEB 2003 HIGHEST RN 485316-86-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09840503.str

```
L1      STRUCTURE UPLOADED

=> activate f9840503/a
L2              STR
L3         1125 SEA FILE=REGISTRY SSS FUL L2

=> s l1 sub=l3 ful
FULL SUBSET SEARCH INITIATED 11:02:21 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -   1085 TO ITERATE

100.0% PROCESSED    1085 ITERATIONS                          720 ANSWERS
SEARCH TIME: 00.00.01

L4          720 SEA SUB=L3 SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    35.70      36.12

FILE 'CAPLUS' ENTERED AT 11:02:35 ON 04 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Feb 2003  VOL 138 ISS 6
FILE LAST UPDATED: 3 Feb 2003  (20030203/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l4
L5          135 L4

=>
Uploading 09840503.str

L6      STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6              STR
```



G1 CN,O,S,Hy,[@1]

G2 C,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l6 sub=l3 ful
REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SUBSET SEARCH INITIATED 11:05:31 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 1085 TO ITERATE

100.0% PROCESSED 1085 ITERATIONS 31 ANSWERS
SEARCH TIME: 00.00.04

L7 31 SEA SUB=L3 SSS FUL L6

SUBSET IS IGNORED AS A SCOPE FOR THIS SEARCH
L8 1 L7

=> d scan

L8 1 ANSWERS CAPLUS COPYRIGHT 2003 ACS
IC ICM C07D413-00
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
TI Preparation of 6-(5-oxazolyl)-4(1H)-quinolinones as inhibitors of IMPDH enzyme
ST oxazolyl quinolinone prepn inosine monophosphate dehydrogenase enzyme

inhibitor; quinolinone oxazolyl prepn allograft rejection treatment

IT Transplant rejection
(allotransplant, treatment; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT Allergy
(hypersensitivity, treatment of T-cell mediated; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT Reperfusion
(injury, treatment; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT Anti-inflammatory agents
Antitumor agents
Antiviral agents
Fungicides
Immunosuppressants
(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT Proliferation inhibition
(proliferation inhibitors; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT Blood vessel, disease
Psoriasis
(treatment; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT 9036-21-9, Phosphodiesterase IV
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor for co-administration with IMPDH inhibitor; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT 21575-91-7P 75476-86-7P, 6-Bromo-2,3-dihydro-1H-inden-1-ol 83823-59-0P, 3-Methyl-.beta.-oxobenzenebutanoic acid ethyl ester 136507-15-8P 150529-73-0P, 3-Bromophenylacetic acid methyl ester 198821-77-1P 198821-78-2P 198821-79-3P 228707-96-8P, 3-[(4-Methoxyphenyl)methoxy]benzoic acid 347184-75-2P, 3-[(4-Methoxyphenyl)methoxy]benzoic acid methyl ester 371249-68-2P 371249-70-6P 371249-73-9P 371249-74-0P 371249-76-2P 371249-78-4P, 3-(Trimethylsilylethynyl)phenylacetic acid methyl ester 371249-79-5P, 3-Ethynylphenylacetic acid 371249-81-9P, 3-(3-Methoxycarbonylphenyl)-3-oxopropanoic acid ethyl ester 371249-82-0P, 3-(3-Methoxycarbonylphenyl)-3-(methylamino)-2-propenoic acid ethyl ester 371249-83-1P, 3-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-3-(3-methoxycarbonylphenyl)-2-propenoic acid ethyl ester 371249-89-7P, 6-Bromo-1-(dimethylamino)-2,3-dihydro-1H-indene 371249-90-0P, 1-(Dimethylamino)-2,3-dihydro-6-[(trimethylsilyl)ethynyl]-1H-indene 371249-92-2P, 1-(Dimethylamino)-6-ethynyl-2,3-dihydro-1H-indene 371249-94-4P, 6-Bromo-2,3-dihydro-1-methoxy-1H-indene 371249-95-5P, 2,3-Dihydro-1-methoxy-6-[(trimethylsilyl)ethynyl]-1H-indene 371249-96-6P, 6-Ethynyl-2,3-dihydro-1-methoxy-1H-indene 371251-07-9P, 6-Bromo-2,3-dihydro-N-methyl-1H-inden-1-amine 371251-08-0P, 6-Bromo-1-chloroindane 371251-09-1P 371251-10-4P 371251-11-5P 371251-14-8P, 1-(6-Bromo-2,3-dihydro-1H-inden-1-yl)pyrrolidine 371251-15-9P, 1-(6-Ethynyl-2,3-dihydro-1H-inden-1-yl)pyrrolidine 371251-17-1P, 4-(6-Bromo-2,3-dihydro-1H-inden-1-

yl)morpholine 371251-18-2P, 4-(6-Ethynyl-2,3-dihydro-1H-inden-1-yl)morpholine 371251-20-6P, 1-(6-Ethynyl-2,3-dihydro-1H-inden-1-yl)azetidine 371251-22-8P, 3-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-4-(3-methylphenyl)-2-butenoic acid ethyl ester 371251-23-9P, 6-Ethynyl-2,3-dihydro-2-methyl-1H-isoindole 371251-24-0P, 3-[(4-Methoxyphenyl)methoxy]-.beta.-oxobenzenepropanoic acid ethyl ester 371251-25-1P, 3-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-3-[3-[(4-methoxyphenyl)methoxy]phenyl]-2-propenoic acid ethyl ester 371251-26-2P, 7-Methoxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-6-(5-oxazolyl)-4-(phenylmethoxy)quinoline 371251-27-3P, 3-[7-Methoxy-6-(5-oxazolyl)-4-(phenylmethoxy)-2-quinolinyl]phenol 371251-28-4P, 2-[3-[7-Methoxy-6-(5-oxazolyl)-4-(phenylmethoxy)-2-quinolinyl]phenoxy]-N,N-dimethylethanamine 371251-31-9P 371251-32-0P, N-[5-Methoxy-4-(5-oxazolyl)-2-(thiocyanato)phenyl]acetamide 371251-33-1P, N-[5-Methoxy-4-(5-oxazolyl)-2-[(2-oxo-2-phenylethyl)thio]phenyl]acetamide 371251-34-2P, N-[5-Methoxy-4-(5-oxazolyl)-2-[(2-oxo-2-phenylethyl)sulfonyl]phenyl]acetamide 371251-37-5P, 2-Amino-4-methoxy-5-(5-oxazolyl)benzoic acid methyl ester 371251-38-6P, 2-Amino-4-methoxy-5-(5-oxazolyl)benzoic acid 371251-39-7P, 2-Amino-4-methoxy-5-(5-oxazolyl)benzoic acid 2-oxo-2-phenylethyl ester 371251-49-9P, 2-Bromo-1-(2,3-dihydro-3-methoxy-1H-inden-5-yl)ethanone 371251-52-4P, 5-Bromo-2,3-dihydro-N,N-dimethyl-1H-inden-1-amine 371251-56-8P, 5-Bromo-2,3-dihydro-3-methoxy-1,1-dimethyl-1H-indene 371251-67-1P 371251-69-3P, 7-Methoxy-4-(methoxymethoxy)-2-[4-methyl-3-(phenylmethoxy)phenyl]-6-(5-oxazolyl)quinoline 371251-71-7P, 5-[7-Methoxy-4-(methoxymethoxy)-6-(5-oxazolyl)-2-quinolinyl]-2-methylphenol 371251-85-3P, 2-Amino-4-methoxy-5-(5-oxazolyl)benzoic acid 2-[2,3-dihydro-3-(dimethylamino)-1H-inden-5-yl]-2-oxoethyl ester 371251-90-0P, 5-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione 371251-95-5P, 5-[(3,4-Dimethoxyphenyl)(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione 371251-96-6P 371252-00-5P, 5-[[3-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl](methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione 371252-02-7P, 5-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino](methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione 371252-03-8P, 5-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino](methylamino)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione 371252-05-0P 371252-07-2P 371252-08-3P 371252-10-7P, 2-[2,3-Dihydro-3-(methylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone hydrochloride 371252-23-2P, 5-[[5-[(Dimethylamino)methyl]-3-thienyl]-(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT 61413-54-5, 4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase IV inhibitor for co-administration with IMPDH inhibitor; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT 371249-67-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 6-(5-oxazolyl)-4(1H)-quinolinones as inhibitors of IMPDH enzyme)

IT 371249-88-6P, 2-[2,3-Dihydro-3-(dimethylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT 371251-98-8P, (R)-2-[3-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-99-9P, (S)-2-[3-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT 371249-69-3P 371249-72-8P 371249-75-1P **371249-77-3P**
371249-80-8P, 3-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]benzoic acid methyl ester 371249-84-2P, 2-[3-(Hydroxymethyl)phenyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
371249-85-3P, 2-[3-(1-Hydroxy-1-methylethyl)phenyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371249-86-4P, 7-Methoxy-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone 371249-91-1P, 7-Methoxy-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone trifluoroacetic acid salt 371249-93-3P, 2-(2,3-Dihydro-3-methoxy-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
371249-97-7P 371249-98-8P 371249-99-9P 371250-00-9P 371250-01-0P
371250-03-2P **371250-04-3P 371250-05-4P**
371250-06-5P 371250-07-6P 371250-09-8P
371250-11-2P 371250-12-3P **371250-14-5P** 371250-15-6P
371250-16-7P 371250-17-8P **371250-18-9P 371250-20-3P**
371250-22-5P 371250-23-6P 371250-25-8P 371250-27-0P
371250-29-2P 371250-31-6P 371250-33-8P 371250-35-0P
371250-37-2P 371250-39-4P 371250-41-8P 371250-43-0P
371250-45-2P 371250-47-4P 371250-48-5P 371250-49-6P 371250-50-9P
371250-51-0P 371250-52-1P 371250-53-2P 371250-54-3P 371250-55-4P
371250-56-5P 371250-57-6P 371250-58-7P, 7-Methoxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone
371250-59-8P, 2-(3-Hydroxyphenyl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371250-60-1P, 2-[3-[2-(Dimethylamino)ethoxy]phenyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371250-61-2P, 2-(2,3-Dihydro-2-methyl-1H-isoindol-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371250-62-3P 371250-63-4P 371250-64-5P 371250-65-6P
371250-66-7P 371250-67-8P 371250-68-9P 371250-69-0P 371250-70-3P
371250-71-4P 371250-72-5P 371250-73-6P **371250-74-7P**
371250-75-8P 371250-76-9P **371250-77-0P** 371250-78-1P
371250-79-2P 371250-80-5P 371250-81-6P 371250-82-7P 371250-83-8P
371250-84-9P 371250-85-0P 371250-86-1P 371250-87-2P 371250-88-3P
371250-89-4P 371250-90-7P 371250-91-8P 371250-92-9P 371250-93-0P
371250-94-1P 371250-95-2P 371250-96-3P 371250-97-4P
371250-98-5P 371250-99-6P 371251-00-2P 371251-01-3P 371251-02-4P
371251-03-5P 371251-04-6P 371251-05-7P **371251-06-8P**
371251-12-6P, 2-[2,3-Dihydro-3-(methylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-13-7P, 2-[2,3-Dihydro-3-(1-pyrrolidinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
371251-16-0P, 2-[2,3-Dihydro-3-(4-morpholinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-19-3P, 2-[3-(1-Azetidinyl)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone

371251-21-7P, 7-Methoxy-2-[(3-methylphenyl)methyl]-6-(5-oxazolyl)-4(1H)-quinolinone 371251-29-5P, 7-Methoxy-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone 371251-30-8P, 6-Methoxy-7-(5-oxazolyl)-3-phenyl-4H-1,4-benzothiazine 1,1-dioxide 371251-35-3P, 6-Methoxy-3-(4-methoxyphenyl)-7-(5-oxazolyl)-4H-1,4-benzothiazine 1,1-dioxide 371251-36-4P, 3-Hydroxy-7-methoxy-6-(5-oxazolyl)-2-phenyl-4(1H)-quinolinone 371251-40-0P, 3-Hydroxy-7-methoxy-2-(2-methylphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone 371251-41-1P, 3-Hydroxy-7-methoxy-2-(3-methylphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone 371251-42-2P, 3-Hydroxy-7-methoxy-2-(4-methylphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone 371251-43-3P, 2-(3,4-Dimethylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-44-4P, 3-Hydroxy-7-methoxy-2-(4-methoxyphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone 371251-45-5P, 2-(4-Chloro-3-methylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-47-7P, 2-(4-Chloro-3-methylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone trifluoroacetate 371251-48-8P, 2-(2,3-Dihydro-3-methoxy-1H-inden-5-yl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-50-2P, 3-Hydroxy-7-methoxy-2-[2-(methylsulfonyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone 371251-51-3P, 2-[1-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-53-5P, 2-(2,3-Dihydro-3-methoxy-2,2-dimethyl-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-55-7P, 2-(2,3-Dihydro-3-methoxy-1,1-dimethyl-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-57-9P, trans-2-[3-(Dimethylamino)-2,3-dihydro-2-methoxy-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-60-4P, trans-2-[3-(Dimethylamino)-2,3-dihydro-2-hydroxy-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-61-5P**, trans-6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-ol methylcarbamate **371251-62-6P**, Ethylcarbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-63-7P**, (1-Methylethyl)carbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-64-8P**, (2-Chloroethyl)carbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-65-9P**, Imidodicarbonic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl methyl ester 371251-66-0P, 7-Methoxy-2-[4-methyl-3-(phenylmethoxy)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone 371251-68-2P, 2-(3-Hydroxy-4-methylphenyl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-70-6P, 7-Methoxy-2-[3-(2-methoxyethoxy)-4-methylphenyl]-6-(5-oxazolyl)-4(1H)-quinolinone 371251-72-8P, 7-Methoxy-2-[4-methyl-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone 371251-73-9P 371251-74-0P 371251-75-1P 371251-76-2P 371251-77-3P 371251-78-4P 371251-79-5P 371251-80-8P 371251-81-9P 371251-82-0P, 6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-N,N,N-trimethyl-1H-inden-1-aminium 371251-83-1P, 2-[3-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-86-4P, 1,4-Dihydro-3-hydroxy-7-methoxy-2-(4-methylphenyl)-4-oxo-6-quinolinecarbonitrile 371251-88-6P, 1,4-Dihydro-3-hydroxy-7-methoxy-2-(3-methylphenyl)-4-oxo-6-quinolinecarbonitrile 371251-89-7P, 7-Methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-91-1P, 7-Methoxy-2-(methylthio)-6-(5-oxazolyl)-4(1H)-quinolinone 371251-92-2P, 2-(2,3-Dihydro-3-hydroxy-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-94-4P, 2-(3,4-Dimethoxyphenyl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-97-7P, 2-[5-[(Dimethylamino)methyl]-3-thienyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371252-01-6P, 7-Methoxy-2-(methylamino)-6-(5-

oxazolyl)-4(1H)-quinolinone 371252-04-9P, 2-(Dimethylamino)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371252-06-1P 371252-09-4P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methylacetamide **371252-11-8P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-2-methoxy-N-methylacetamide **371252-12-9P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-1H-imidazol-1-acetamide **371252-13-0P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-4-morpholineacetamide **371252-14-1P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-2H-1,2,3-triazol-2-acetamide **371252-15-2P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-1H-1,2,3-triazol-1-acetamide **371252-16-3P 371252-17-4P**, Dimethylcarbamic acid 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl ester 371252-18-5P, 2-[2,3-Dihydro-1-(1-pyrrolidinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371252-19-6P**, 4-Acetyl-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-3,4-dihydro-2H-1,4-benzoxazine 371252-20-9P 371252-21-0P, 7-Methoxy-2-[4-(4-morpholinylmethyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone 371252-22-1P, 6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-N,N,N-trimethyl-1H-inden-1-aminium iodide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT 9028-93-7, Inosine monophosphate dehydrogenase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT 371251-58-0P, trans-6-Bromo-2,3-dihydro-2-hydroxy-N,N-dimethyl-1H-inden-1-amine
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

IT 70-11-1, 2-Bromoacetophenone 79-44-7, Dimethylcarbamyl chloride 94-02-0, Ethyl benzoylacetate 107-99-3, 1-Chloro-2-dimethylaminoethane 109-90-0, Ethyl isocyanate 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 288-88-0, 1H-1,2,4-Triazole 503-29-7, Azetidine 541-41-3, Ethylchloroformate 619-41-0, 2-Bromo-4'-methylacetophenone 621-36-3, m-Tolylacetic acid 627-42-9, 2-Chloroethyl methyl ether 766-97-2, p-Methylphenylacetylene 824-94-2, p-Methoxybenzyl chloride 1066-54-2, (Trimethylsilyl)acetylene 1711-09-7, 3-Bromobenzoyl chloride 1795-48-8, Isopropyl isocyanate 1877-71-0, Monomethyl isophthalate 1878-67-7, 3-Bromophenylacetic acid 1943-83-5, 2-Chloroethyl isocyanate 2632-13-5, 2-Bromo-4'-methoxyacetophenone 2633-50-3, 2-Bromo-3',4'-dimethylacetophenone 2859-78-1, 4-Bromoveratrole 3240-94-6 5843-42-5, Methyl isocyanatoformate 6148-64-7, Potassium ethyl malonate 13120-77-9, 4-Nitro-2-methoxytoluene 14548-39-1, 6-Bromo-1-indanone 15568-85-1, 5-(Methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 19438-10-9, Methyl 3-hydroxybenzoate 38870-89-2, Methoxy acetyl chloride 51012-64-7, 2-Bromo-3'-methylacetophenone 51012-65-8, 2-Bromo-2'-methylacetophenone 52694-50-5, 3-Chloromethyl-1-methylpiperidine 75476-78-7, 5-Bromoindene 78909-24-7, 4-Bromo-N,N-dimethyl-2-thiophenemethanamine 91448-64-5, Iodoaniline 100981-05-3, 5-[Bis(methylthio)methylene]-2,2-dimethyl-1,3-

dioxane-4,6-dione 107834-37-7, 5-Bromo-2-(N-methyl)isoindoline 124369-60-4, 5-Bromo-3,3-dimethyl-1-hydroxyindane 158330-91-7, 5-Bromo-1-chloroindane 371249-87-5, 2-[3-(4-Methyl-1-piperazinyl)phenyl]-7-methoxy-4-methoxymethoxy-6-(5-oxazolyl)quinoline 371251-46-6, 2-Amino-4-methoxy-5-(5-oxazolyl)benzoic acid 2-(4-chloro-3-methylphenyl)-2-oxoethyl ester 371251-54-6, 5-Bromo-2,2-dimethyl-1-hydroxyindane 371251-59-1, trans-6-Bromo-2,3-dihydro-2-methoxy-N,N-dimethyl-1H-inden-1-amine 371251-84-2, 6-(Bromoacetyl)-2,3-dihydro-N,N-dimethyl-1H-inden-1-amine 371251-87-5, 2-Amino-5-cyano-4-methoxybenzoic acid 2-(4-methylphenyl)-2-oxoethyl ester 371251-93-3, 2,2-Dimethyl-5-[(methylthio)-[3-[[tris(1-methylethyl)silyl]oxy]-1H-inden-5-yl]methylene]-1,3-dioxane-4,6-dione
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

ALL ANSWERS HAVE BEEN SCANNED

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.83	74.34

FILE 'REGISTRY' ENTERED AT 11:06:35 ON 04 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2003 HIGHEST RN 485316-86-7
DICTIONARY FILE UPDATES: 3 FEB 2003 HIGHEST RN 485316-86-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d his

(FILE 'HOME' ENTERED AT 10:59:59 ON 04 FEB 2003)

FILE 'REGISTRY' ENTERED AT 11:01:24 ON 04 FEB 2003
L1 STRUCTURE UPLOADED
ACTIVATE F9840503/A

L2 STR
L3 1125 SEA FILE=REGISTRY SSS FUL L2

```
L4          720 S L1 FUL SUB=L3

     FILE 'CAPLUS' ENTERED AT 11:02:35 ON 04 FEB 2003
L5          135 S L4
L6              STRUCTURE UPLOADED
                S L6

     FILE 'REGISTRY' ENTERED AT 11:05:31 ON 04 FEB 2003
L7           31 S L6 FUL SUB=L3

     FILE 'CAPLUS' ENTERED AT 11:05:36 ON 04 FEB 2003
L8            1 S L7 SUBSET=L3 FUL

     FILE 'REGISTRY' ENTERED AT 11:06:35 ON 04 FEB 2003

=> s l6 sub=l3 ful
FULL SUBSET SEARCH INITIATED 11:06:49 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -   1085 TO ITERATE

100.0% PROCESSED    1085 ITERATIONS                          31 ANSWERS
SEARCH TIME: 00.00.01

L9           31 SEA SUB=L3 SSS FUL L6

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               35.30     109.64

FILE 'CAPLUS' ENTERED AT 11:06:55 ON 04 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Feb 2003  VOL 138 ISS 6
FILE LAST UPDATED: 3 Feb 2003  (20030203/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l9
L10          1 L9

=> d abs ibib hitstr 1-
YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y

L10  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS
```

GI



I



II

AB Title compds. I [wherein X1 = CO, SO, or SO2; X2 = CR3 or N; X3 = NH, O, or S; X4 = CR4 or N; X5 = CR5 or N; X6 = CR6 or N] were prepd. were prepd. as inosine monophosphate dehydrogenase (IMPDH) enzyme inhibitors. For example, acetalization of 4-nitro-2-methoxytoluene with AcOH (51%), redn. to the aldehyde (91%), and cycloaddn. with (p-tolylsulfonyl)methyl isocyanate gave 5-(4-nitro-2-methoxyphenyl)oxazole (84%), which was reduced to the amine (95%). Alkylation with Et benzoylacetate and cyclization afforded the 6-(5-oxazolyl)-4(1H)-quinolinone II. Thus, I are useful as therapeutic agents for IMPDH-assocd. disorders, such as allograft rejection (no data).

ACCESSION NUMBER: 2001:798220 CAPLUS
DOCUMENT NUMBER: 135:344472
TITLE: Preparation of 6-(5-oxazolyl)-4(1H)-quinolinones as inhibitors of IMPDH enzyme
INVENTOR(S): Iwanowicz, Edwin J.; Watterson, Scott H.; Dhar, T. G. Murali; Pitts, William J.; Gu, Henry H.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 263 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081340	A2	20011101	WO 2001-US12900	20010419
WO 2001081340	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1276739	A2	20030122	EP 2001-928708	20010419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002040022	A1	20020404	US 2001-840503	20010423

PRIORITY APPLN. INFO.: US 2000-199420P P 20000424
WO 2001-US12900 W 20010419

OTHER SOURCE(S): MARPAT 135:344472

IT **371249-77-3P 371249-80-8P**, 3-[1,4-Dihydro-7-methoxy-6-(5-

oxazolyl)-4-oxo-2-quinolinyl]benzoic acid methyl ester
371250-04-3P 371250-05-4P 371250-06-5P
371250-07-6P 371250-09-8P 371250-14-5P
371250-18-9P 371250-20-3P 371250-22-5P
371250-37-2P 371250-74-7P 371250-77-0P
371250-94-1P 371251-06-8P 371251-61-5P,
trans-6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-ol methylcarbamate
371251-62-6P, Ethylcarbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-63-7P**, (1-Methylethyl)carbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-64-8P**, (2-Chloroethyl)carbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-65-9P**, Imidodicarbonic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl methyl ester **371252-06-1P 371252-09-4P**,
N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methylacetamide **371252-11-8P**,
N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-2-methoxy-N-methylacetamide **371252-12-9P**,
N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-1H-imidazol-1-acetamide **371252-13-0P**,
N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-4-morpholineacetamide **371252-14-1P**,
N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-2H-1,2,3-triazol-2-acetamide **371252-15-2P**
, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-1H-1,2,3-triazol-1-acetamide
371252-16-3P 371252-17-4P, Dimethylcarbamic acid 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl ester **371252-19-6P**, 4-Acetyl-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-3,4-dihydro-2H-1,4-benzoxazine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

RN 371249-77-3 CAPLUS
CN Benzeneacetic acid, 3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 371249-80-8 CAPLUS
CN Benzoic acid, 3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 371250-04-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 371250-05-4 CAPLUS
CN Acetamide, N-[3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]phenyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)



RN 371250-06-5 CAPLUS
CN Acetamide, 2-(acetyloxy)-N-[3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371250-07-6 CAPLUS
CN 4-Morpholineacetamide, N-[3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371250-09-8 CAPLUS
CN Benzoic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 371250-14-5 CAPLUS
CN 2-Quinolinepropanamide, N,N-diethyl-1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 371250-18-9 CAPLUS
CN Benzenebutanoic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 371250-20-3 CAPLUS

CN Benzenebutanoic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 371250-22-5 CAPLUS
CN Benzeneacetic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 371250-37-2 CAPLUS
CN Benzenepropanoic acid, 3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



RN 371250-74-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2-methylphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 371250-77-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[5-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2-methylphenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 371250-94-1 CAPLUS
CN Carbamic acid, dimethyl-, 7-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1,2,3,4-tetrahydro-1-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 371251-06-8 CAPLUS
CN Carbamic acid, [6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 371251-61-5 CAPLUS
CN 4(1H)-Quinolinone, 2-[(2R,3R)-3-(dimethylamino)-2,3-dihydro-2-[[(methylamino)carbonyl]oxy]-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-62-6 CAPLUS
CN Carbamic acid, ethyl-, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-63-7 CAPLUS
CN Carbamic acid, (1-methylethyl)-, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-64-8 CAPLUS
CN Carbamic acid, (2-chloroethyl)-, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-

oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371251-65-9 CAPLUS
CN Imidodicarbonic acid, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 371252-06-1 CAPLUS
CN Carbamic acid, [6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 371252-09-4 CAPLUS
CN Acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-11-8 CAPLUS
CN Acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-12-9 CAPLUS
CN 1H-Imidazole-1-acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-13-0 CAPLUS
CN 4-Morpholineacetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-14-1 CAPLUS
CN 2H-1,2,3-Triazole-2-acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-15-2 CAPLUS
CN 1H-1,2,3-Triazole-1-acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 371252-16-3 CAPLUS
CN Carbamic acid, [6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 371252-17-4 CAPLUS
CN Carbamic acid, dimethyl-, 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl ester (9CI) (CA INDEX NAME)



RN 371252-19-6 CAPLUS
CN 2H-1,4-Benzoxazine, 4-acetyl-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)


Ac
MeO
H
N
N
O
N
O
O